SPAS: The first subject has been enrolled in the Phase III clinical trial of Litanoprost eye drops

SPAS announced that the Phase III clinical trial of its drug Litanoprost Eye Drops organized by the company completed the enrollment of the first subject on October 23, 2025. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study to evaluate its efficacy and safety in treating dry eye in the Chinese population. As of the announcement date, the total R&D investment for this project is approximately 19.1515 million yuan. The drug has a long and complex cycle from clinical trials to production, and the development may be terminated due to various potential issues. The company will disclose progress in a timely manner